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Osteogenesis imperfecta, discussed in Baldridge et al. 2008 is an inherited bone fragility disorder with a wide range of clinical
severity that in the majority of cases is caused by mutations in COL1A1 or COL1A2, the genes that encode the two collagen type I
alpha chains. Here we describe genotype-phenotype correlations in OI patients who have mutations aﬀecting collagen type I. This
paper is based on ﬁndings in a large single-centre OI population and a review of the literature.
1.Introduction
Osteogenesis imperfecta [1] is a heritable skeletal disorder
characterized by bone fragility and often short stature.
Extraskeletal features include blue sclerae, dentinogenesis
imperfecta (DI), and a variable degree of postpubertal
hearing loss.
The spectrum of clinical severity is wide, ranging from
nearly asymptomatic individuals with a mild predisposition
to fractures, normal stature and normal lifespan, to severe
bone deformities, mobility impairments, and very short
stature to perinatal lethality [2].
Classically four types of OI are distinguished, as
described by Sillence et al. in 1979 [3]. This classiﬁcation
is based on clinical features. OI type I is the mildest form.
Patients usually have normal or slightly short stature with
straight long bones and blue sclerae. DI is infrequent in
this type. The main clinical issue in OI type I concerns the
spine,wherevertebralcompressionfracturescanleadtomild
scoliosis. OI type II is usually lethal during the perinatal
period, with in utero onset of severe long-bone deformities
and rib fractures that lead to respiratory compromise and
eventually death. OI type III is the most severe form of OI
that is compatible with life. Patients have severe short stature
and severe long bone deformities, with reduced mobility.
They typically have DI and blue sclera. Scoliosis can lead
to fatal respiratory compromise. OI type IV is a moderately
severe form of OI with multiple fractures, mild to moderate
bone deformities, and variable short stature. Sclerae in this
type are white or grey and DI is not a constant feature.
Even though this classiﬁcation is widely used, it is
somewhat subjective in nature and depends on the amount
of information that is available at any given time. For
example, it can occur that a fetus is diagnosed with OI type
II, the lethal form, on prenatal ultrasound, but after birth
turns out to be less severely aﬀected than initially thought
a n di se v e n t u a l l yr e c l a s s i ﬁ e da sO It y p eI I Io re v e nt y p e
VI, if adequate management is initiated early on. In fact,
the aim of current multidisciplinary treatment approaches
including physiotherapy, occupational therapy, bisphospho-
nate treatment, and corrective surgical interventions is to
shift the severity of the skeletal phenotype from severe
(corresponding to OI type III) to moderate (type IV) and
from moderate to mild (type I). Thus, an initial OI type
classiﬁcation for a speciﬁc patient can change if treatments
or other factors decrease the severity of the phenotype.
The majority of OI patients have a mutation in either
the COL1A1 or the COL1A2 gene, the two genes coding
for alpha 1 and alpha 2 chains of collagen type I. Collagen
type I is a heterotrimer consisting of two alpha 1 chains
and one alpha 2 chain. It is initially synthesized as a pro-
alpha chain with a propeptide at each end (N-propeptide
and C-propeptide). The propeptides are necessary for pro-
alpha chain association and triple helix formation that2 Journal of Osteoporosis
starts at the carboxy-terminal propeptide and extends to
the aminoterminal propeptide in a zipper-like manner. The
triplehelicaldomainsarecomposedofuninterruptedrepeats
of the Gly-X-Y tripeptide. Triple helix formation requires a
glycine residue in every third position of the chains because
glycine is the only residue small enough to ﬁt into the
restricted space at the inside of the helix.
Two general classes of mutations in collagen type I are
associated with OI. The ﬁrst class of mutation leads to
haploinsuﬃciency, typically resulting in mild OI type I [4].
Haploinsuﬃciency is usually the consequence of a nonsense
mutation or a frame shift mutation that introduces a
premature termination codon in the coding sequence of one
COL1A1allele.Thisinitiatesnonsense-mediateddecayofthe
mRNA [5]. The result of these mutations is a quantitative
defect in collagen type I, as only about half of the normal
amount of the protein is produced. However, the collagen
type I protein that is produced has a normal structure.
Some splice-site mutations and C-propeptide mutations in
COL1A1 can also lead to haploinsuﬃciency.
The second class of mutation consists of sequence
abnormalities that lead to structural mutations in collagen
type I. This includes helical glycine mutations, which are
the most frequent type of mutations leading to OI. Such
mutationsusuallyreplaceglycinebyanotheraminoacid.Any
mutation that disrupts the Gly-X-Y sequence of the collagen
triple helix will result in impaired collagen function. Such
mutations impair triple helix formation, its stability, and its
interactions with the extracellular matrix. Very few mutant
collagen monomers are needed to disrupt the structure of
the various multitrimer assemblies. Glycine mutations in
collagen type I thus exert what is known as a dominant
negative eﬀect.
Many studies on individual OI patients or small patient
groups have examined the molecular and cellular conse-
quences of collagen type I mutations, especially in skin
ﬁbroblasts, but less information is available on osteoblasts.
So far, very little is known about how a speciﬁc collagen type
I mutation leads to a particular phenotype. As a general rule,
the phenotypic severity depends on the aﬀected alpha chain,
the position of the mutation, the substituting amino acid, or
the combination of these three variables.
As of June 2011, more than 2000 diﬀerent collagen type I
mutations have been identiﬁed in OI patients and are listed
in a database (http://www.le.ac.uk/ge/collagen/)[ 6, 7]. With
the constant increase in the number of identiﬁed mutations
in COL1A1 and COL1A2, genotype-phenotype correlation
becomes more and more pertinent.
In this paper, we provide an overview of genotype-
phenotype correlations in OI patients who have mutations
aﬀecting collagen type I.
2.Lethality
A 2007 compilation of 832 triple helical collagen type I
mutations distinguished two main classes of mutations [6–
8]: point mutations that cause the substitution of a triple
helical glycine residue by another amino acid (n = 682) and
mutations that alter splice sites (n = 150). The majority of
these mutations caused OI types II, III, or IV.
The only phenotypic characteristic that could be evalu-
ated in this report was whether the individuals carrying each
mutation had survived the immediate postnatal period or
not. Glycine substitutions in the alpha 1 chain of collagen
type I were more frequent than mutations in the alpha 2
chain (57% versus 43%) and more likely to have a lethal
outcome (36% of alpha 1 and 19% of alpha 2 mutations were
lethal). Substitutions in the ﬁrst 200 residues of the alpha 1
chain were found to be usually nonlethal.
Two exclusively lethal regions in the alpha 1 chain
(helix positions 691–823 and 910–964), and eight clusters
of lethality in the alpha 2 chain were identiﬁed. These
lethal areas align with major ligand binding regions for
extracellular matrix proteins, which might explain the lethal
outcome of mutations occurring at these sites. Even though
the identiﬁcation of these “lethal regions” provides a useful
rule of thumb, there are certainly many exceptions to the
rule. For example, a recent study identiﬁed seven individuals
who had mutations in the putative lethal regions of alpha
1( n = 1) and alpha 2 (n = 6) and who did not have a
lethal outcome [9]. This observation is important for genetic
counseling, especially in the context of prenatal diagnosis.
Glycine substitutions are more likely to have a lethal
outcome when the substituting amino acid in the alpha 1
chainischarged(likeaspartateorglutamateacidorarginine)
or branched (valine) and aﬀects a glycine at an amino
acid position that is C-terminal of position 200 [8]. No
such relationship was found for the alpha 2 chain. Glycine
substitutions in the alpha 2 chain are more likely to be
concordant for the outcome than glycine substitutions in the
alpha 1 chain.
3. Deformities and Fracturesat Birth
In a study on 117 OI patients, no signiﬁcant relationship was
foundbetweenthepresenceoflimbdeformitiesandfractures
at birth and either the type of aﬀected collagen type I alpha
chainorthepositionoftheglycinemutationwithinthealpha
chain [9]. A smaller percentage of patients with arginine
substitutions in alpha 1 had fractures or deformities at birth
than patients with serine substitutions (44% versus 83%; P
< 0.05). There was no relationship between the substituting
amino acid and the prevalence of fractures or deformities at
birth in the alpha 2 chain.
4.Anthropometry
In a study of 86 OI patients, mean standing height was
reduced in all groups of patients but height reduction
was signiﬁcantly more marked in patients with qualitative
collagen defects than in those with quantitative defects
[10]. The same pattern was observed for truncal height
and arm span z-score. Arm span to height ratio was
increased in children with qualitative collagen defects (P <
0.05), but not in those with a quantitative collagen defect.
Head circumference was increased in all OI types, butJournal of Osteoporosis 3
signiﬁcantly more so in patients with qualitative collagen
defects. Head circumference was disproportionate to height.
The disproportion was again more pronounced in patients
with qualitative collagen defects.
A recent study in 161 OI patients (median age: 13 years)
who had glycine mutations in the triple helical domain of
collagen type I found that mutations in COL1A1 and in
COL1A2ledtosimilaraverageheightz-scores[9].Aninverse
relationship was found between the height and the location
of the mutation in the triple helical domain of the alpha 2
chain (Figure 1(b)). Thus, a mutation closer to the carboxy-
terminal end of the triple helical domain of alpha 2 had
am o r ed e t r i m e n t a le ﬀect on height. No such correlation
w a so b s e r v e di nt h ea l p h a1c h a i n( Figure 1(a)). Results in
the alpha 2 chain are consistent with the gradient model of
disease severity, which posits that mutations at the carboxy-
terminal end of the alpha 2 chain are more disruptive to
triple helix formation and therefore cause a more severe
phenotype.
Height is not only aﬀected by the location of the glycine
mutation but also by the speciﬁc substituting amino acid
[9]. Serine substitutions are the most common type of
mutations in both the alpha 1 and the alpha 2 chain
and seem to lead to a shorter average stature when they
aﬀect the alpha 1 chain [9]. Arginine substitutions are
the second most frequent mutations in the alpha 1 chain.
Comparedtopatientswithserinesubstitutions,patientswith
arginine mutations on average had less severe short stature
[9]. Aspartate substitutions are the second most frequent
mutationsinthealpha2chainandonaverageleadtoasevere
short stature. Other substituting amino acids in either chain
were not frequent enough for statistical analysis.
In a study on the relationship between genotype and
skeletal phenotype in 192 OI patients (age range 3 weeks to
16.9years),itwasnoted thatpatientswithhaploinsuﬃciency
mutations on average were taller (height z-score −1.3 (SD:
1.1) than patients with helical mutations in the alpha 1
(meanheightz-score −5.5(SD:3.1))oralpha2chains(mean
height z-score −5.3 (SD: 3.3)) [11].
5. DentalPhenotype
DI is histologically characterized by an abnormal dentine
structure [12]. Clinically it is deﬁned by discoloration of
the teeth that ranges from grey-brown to opalescent blue.
In a study of 88 OI patients, the prevalence of DI was 28%
[13]. The majority of patients with DI had a qualitative
collagen defect (96%), whereas only a minority of patients
(4%) had a quantitative collagen defect. Lund et al. did not
observeanassociationbetweenDIandanyspeciﬁcstructural
abnormality or any particular position of the abnormality
along the collagen I alpha chains [13].
In an analysis based on genomic DNA sequencing data,
Rauch et al. found that the majority of OI patients with
a glycine mutation have clinically recognizable DI [9]. The
prevalence of DI was similar for mutations aﬀecting the
alpha 1 or the alpha 2 chain (71% versus 66%, resp., P
= 0.53). Among mutations aﬀecting the alpha 1 chain,
arginine substitutions were less often associated with DI
(25%) than serine substitutions (89%). In the same study it
was observed that glycine mutations aﬀecting the ﬁrst 120
amino acids of the collagen type I triple helical domain did
not lead to DI (Figure 2). Although at this point there is
no mechanistic link between collagen type I mutations and
DI, a high degree of concordance for DI was observed for
OI patients who shared the same glycine mutation in the
helical domain. It thus appears that the dental phenotype
is directly linked to the collagen abnormality and is not
signiﬁcantly inﬂuenced by other genetic or environmental
factors.
6. Scleral Hue
Patients with mutations in the helical domain of the alpha 1
chain tend to have blue sclera more often (75%) than those
with mutations in the alpha 2 chain (57%) [9]. It was also
noticed that mutation aﬀecting the ﬁrst 120 amino acids
of the triple helical domain consistently led to blue sclerae
(Figure 3). Among patients who shared the same collagen
type I mutation the concordance for the scleral phenotype
was less than for the dental phenotype. This may be due to
the fact that blue sclera is a more variable feature than DI
and in some patients tends to disappear with age.
7.Skeletal Phenotype
7.1. Bone Mineral Density. In a study on 192 OI patients,
the mean lumbar spine areal bone mineral density (aBMD)
z-score was higher in patients with haploinsuﬃciency
mutations (−3.4 (SD: 1.0)) than in patients with helical
mutations in the alpha 1 chain (−4.9 (SD: 1.5)) or the alpha
2 chain (−5.0 (SD: 1.3)) [11]. After adjustment for age,
sex, and height z-scores, the mean lumbar spine aBMD z-
scores were higher by 0.7 in the haploinsuﬃciency group
compared to both helical mutation groups. The surprisingly
small diﬀerence in aBMD between these two mutation
groups is not reﬂective of the marked diﬀerence in clinical
phenotype, suggesting that factors other than aBMD are
likely to inﬂuence the severity of the bone disease. The same
study found no signiﬁcant association between the lumbar
spine aBMD z-scores and the aﬀected alpha chain or the
substituting amino acid or the position of the mutation on
the triple helical mutations [11].
7.2. Iliac Bone Histomorphometry. A histomorphometric
study in 96 patients showed that bone size, cortical width,
and the amount of trabecular bone were all signiﬁcantly
lower in OI patients than in healthy controls, but no signif-
icant diﬀerence in bone size and the amount of trabecular
bone was found between patients with haploinsuﬃciency
mutations and those with helical glycine mutations [11]
(Figure 4(a)). However, cortical width was higher in the
haploinsuﬃciency group, suggesting that the tissue-level
diﬀerences between the two mutation groups was related
mainly to diﬀerences in bone modeling on periosteal and





























































Figure 1: Relationship between the positions of glycine substitutions in the triple helical domain of type I collagen and height z-scores in
α1 chain of collagen I (a) and α2 chain of collagen I (b). The oblique solid line in B represents the regression line between the position of
serine substitutions in α2 chain of collagen I and height (r = −0.73, P < 0.001; Spearman’s rank correlation). The oblique dashed line in (b)
represents the regression line between the position of aspartate substitutions in α2 chain of collagen I and height (r = −0.75, P < 0.001). A
mutation closer to the carboxy-terminal end of the triple helical domain of alpha 2 chain had a more detrimental eﬀe c to nh e i g h t( b ) .N o









Figure 2: Relationship between the triple helical position of glycine
mutations in collagen type I α chains and the presence (+) or
absence (−) of dentinogenesis imperfecta (DI), adapted from [9].
The genotypic groups diﬀered little in trabecular bone
metabolism. Bone turnover was generally elevated in OI
patients, but this abnormality was more marked in patient
with helical glycine mutations (Figure 4(b)). There was no








Figure 3: Relationship between the triple helical position of glycine
mutations in collagen type I α chains and the presence (+) or
absence (−) of blue sclera, adapted from [9].
obvious correlation between the aﬀected alpha chain, the
position of the mutation, or the substituting amino acid and
the histomorphometric parameters in the helical mutation

























































Figure 4: Iliac bone histomorphometric results in patients with COL1A1 haploinsuﬃciency mutations (HI), as well as with COL1A1 and
COL1A2 mutations leading to glycine substitutions in the helical domain of collagen type I. Results are expressed as a percentage of the
average result in the age-speciﬁc reference range [14]. The letters above the bars indicate the signiﬁcance of the diﬀerence from 100% (i.e.,
the average result in healthy controls): a: P < 0.05; b: P < 0.01; c: P < 0.001. The signiﬁcance of the variation between genotype groups
is indicated by the symbols above the bar groups: ns = not signiﬁcant; ∗P < 0.05; ∗∗P < 0.01; (a) C.Wi: core width; Ct.Wi: cortical width;
BV/TV:bonevolumepertissuevolume;(b)O.Th:osteoidthickness;OS/BS:osteoidsurfaceperbonesurface,Ob.S/BS:osteoblastsurfaceper
bone surface; MAR: mineral apposition rate; MS/BS: mineralizing surface per bone surface; BFR/BS: bone-formation rate per bone surface,




Figure 5: Representative examples of iliac bone samples.(a)Haploinsuﬃciency mutation, in a 4-year-old boy with a c.1981C > T nucleotide
change in COL1A1 that creates a stop codon (p.Gln661X). Core width 4.8mm, cortical width 765μm, bone volume per tissue volume
12.9%. (b) Helical glycine mutation, 9-year-old boy with a c.1090G > A nucleotide change in COL1A2 that creates an amino acid change
(p.Gly364Ser). Core width 4.2mm, cortical width 449μm, and bone volume per tissue volume 8.9%, adapted from [11].
In summary, patients with haploinsuﬃciency mutations
have a milder skeletal phenotype and so far there is no
obvious correlation between the genotype and the skeletal
phenotype in the helical glycine mutation group.
7.3. Wormian Bones. Wormian bones on skull radiography
areacharacteristicbutnotpathognomonicﬁndingofOIand
can sometimes help to diﬀerentiate between OI and child
abuse. Wormian bones are accessory skull bones that are
surrounded by suture lines. An analysis of 195 OI patients
with a median age of 11.8 years found a signiﬁcant number
of Wormian bones in 59% of cases [15]. A smaller study
in adults had found a similar prevalence of Wormian bones
[16].6 Journal of Osteoporosis
Figure 6: Basilar impression on brain MRI. The tip of the odontoid
process (arrow) projects > 5mm above the Chamberlain line (line
between the hard palate and the opisthion which is the midpoint on
the posterior margin of the foramen magnum).
The prevalence of Wormian bones strongly depended
on genotype, as they were present in 29% of patients with
haploinsuﬃciency mutations, 96% of patients with helical
glycine mutation in the alpha 1 chain, 72% of patients with
helical glycine mutation in the alpha 2 chain, 48% of patients
withsplicesitemutations,33%ofpatientswithC-propeptide
mutations [15]. Regression analysis showed that height z-
score and the presence of glycine substitutions were the
main patient characteristics that were associated with the
presence of Wormian bones. Wormian bones were observed
in patients as young as 2 weeks old, suggesting that they are
likely to develop in utero. Evaluation of serial skull X-rays
showed that Wormian bones do not “disappear” with time
but tend to persist.
7.4. Cranial Base Abnormalities. Several cranial base abnor-
malities can be distinguished: Basilar invagination is a pri-
mary developmental anomaly and is radiologically deﬁned
by the upward migration of the top of C2 (the odontoid
process) into the foramen magnum (Figure 6). Basilar
impression is the acquired form of the basilar invagination
and is diagnosed when the odontoid process is positioned far
above the caudalborders of the skull secondaryto an upward
displacement of basilar and condylar regions of the occipital
bone leading to an infolding of the foramen magnum and a
translocation of the upper cervical spine into the brainstem
[17]. Platybasia is deﬁned by the presence of a ﬂat anterior
cranial base angle (the nasion-sella-basion angle) (Figure 7).
A cephalometric analysis of 187 mostly pediatric OI
patientsfoundatleastoneofthesecranialbaseabnormalities
in 22% of patients [19]. Platybasia was the most common
ﬁnding (16%), followed by basilar impression (6%) and
basilar invagination (4%). A similar prevalence of cranial
base abnormalities had been observed in a smaller study of
adult patients [16].
Figure 7: Platybasia: a ﬂat cranial base as a consequence of a ﬂat









Exon 48 Exon 49
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Figure 8: Amino acid sequence of collagen α2 (I) between residues
1087 and 1111. Residues that are part of the triple-helical domain
are shown on black background. The ﬁrst residues of the C-
telopeptide are shown in italics and on gray background. The
asterisk indicates the glycine residue that is aﬀectedinaboywithOI
type IV who has normal height and a normal appearance of hands
and feet, adapted from [18].
Cranial base abnormalities appeared to depend on
genotype, as they were present in 6% of patients with
haploinsuﬃciency mutations, in 43% of patients with helical
glycine substitutions in alpha 1, in 32% of patients with
helical glycine substitutions in alpha 2, and in 17% of
patients with splice-site mutations in either COL1A1 or
COL1A2 [19]. However, regression analyses found that
only the height z-score but not genotype was a signiﬁcant
independent predictive factor of cranial base abnormalities
in OI patients. This suggests that cranial base abnormalities
do not directly result from collagen type I mutations, but
rather depend on the severity of the skeletal phenotype that
is caused by these mutations.
8. Other Genotype-PhenotypeCorrelations
8.1. Intracranial Hemorrhage and Limb Anomalies. As p e c i ﬁ c
phenotype seems to be associated with mutations located
in exon 49 of the COL1A2 gene, which codes for the
carboxy-terminal end of the alpha 2 triple helical domain
[18]( Figure 8). Three unrelated patients with OI type III,
two girls and one boy, with mutations in this area had
small hands and feet, brachydactyly with marked shorteningJournal of Osteoporosis 7
(a) (b)
(c) (d)
Figure 9: Radiographs of hands and feet in a 15-year-old female. Small stubby hands and feet with hypoplastic nails (a, c). Severe shortening
and thinning of all tubular bones including metacarpal and metatarsal bones, especially marked at the distal phalanges (b, d), adapted with
modiﬁcation from [18].
of the distal phalanges, hypoplastic nails and loose skin
around ﬁngers (Figure 9). In addition, these three patients
developed spontaneous intracranial hemorrhage at diﬀerent
ages (between 4 months to 15 years old). So far, there is no
mechanistic explanation for this association.
8.2. Ehlers-Danlos Syndrome (EDS) Association. Nonglycine
substitutions are rarely disease causing in the triple helical
domain of collagen type I. A speciﬁc arginine to cysteine
substitution at position 888 of the alpha 1 triple helical
domain was reported to lead to a phenotype that combined
features of OI and EDS [20]. Other nonglycine substitutions
inalpha1oralpha2havebeenreportedtobeassociatedwith
osteopenia, and vascular rupture [21], Caﬀey disease with
joint laxity [22], and Marfan variant [23].
8.3. Hearing. The relationship between genotype and hear-
ing loss in OI has not been studied in great detail. In
one study on adults with OI, 60% of patients with glycine
substitutions and 70% of patients with haploinsuﬃciency
mutations had hearing loss [24]. The diﬀerent mutations
resulted in overlapping hearing phenotypes and there was
a marked intrafamilial variability in hearing phenotype
between family members with the same mutation. However
there was no statistically signiﬁcant correlation between the
mutated gene or the mutation type and hearing pattern. The
basis of hearing loss in OI is thus likely to be complex and
multifactorial.
9. Summary of Main Points
(i) Glycine-to-serine substitutions are the most frequent
type of mutation in the triple helix domains of the
collagen type I alpha 1 and alpha 2 chains.
(ii) Serine substitutions tend to lead to a more severe
phenotype in the alpha 1 than in the alpha 2 chain.8 Journal of Osteoporosis
(iii) The clinical severity of serine substitutions correlates
withthepositionofthemutationinthealpha2chain,
but not in the alpha 1 chain.
(iv) Substitutions by arginine, aspartate, glutamate, and
valine beyond the ﬁrst 200 amino acid residues
of alpha 1 are generally lethal, but have variable
outcome in alpha 2.
(v) Mutations aﬀecting the ﬁrst 120 amino acids of the
collagen type I triple helix lead to blue sclera but do
not cause dentinogenesis imperfect.
(vi) Glycine substitutions in alpha 1 almost always are
associated with the presence of Wormian bones,
whereas about three quarters of patients with glycine
substitutions in alpha 2 and one quarter of patients
with haploinsuﬃciency mutations have Wormian
bones.
(vii) More than a third of patients with glycine substitu-
tions in the alpha 1 or alpha 2 chain but only 1 in
20 patients with haploinsuﬃciency mutations have
c r a n i a lb a s ea b n o r m a l i t i e s .
(viii) Mutations at the C-terminal end of the alpha 2 chain
are associated with limb anomalies and intracranial
hemorrhage.
(ix) No correlation was found between the mutated gene
or mutation type and the hearing pattern in OI.
It is essential to keep in mind that these are general rules
for genotype phenotype correlation in autosomal dominant
OI patients but exceptions do arise and it is particularly
important to keep this in mind in the context of genetic
counseling speciﬁcally in prenatal cases.
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